Investors

Press releases

2023/03/17

Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR

Read more
2023/03/14

First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima

Read more
2023/03/08

Medivir to present at the Stockholm Corporate Finance Life Science Day

Read more

Presentations

Quarterly report presentations

Events

2023/04/05

Annual Report 2022

Read more
2023/04/27

Interim Report, January - March 2023

Read more
2023/05/04

Annual General Meeting 2023

Read more

Corporate Governance

Medivir Corporate Governance documention.

Annual General Meeting

Documentation from Medivir's Annual General Meetings.